Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Saved in:
| Title: | Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. |
|---|---|
| Authors: | Richardson, Debra L.1,2 (AUTHOR) debra-richardson@ouhsc.edu, Moore, Kathleen N.1,2 (AUTHOR) kathleen-moore@ouhsc.edu, Vergote, Ignace3 (AUTHOR) ignace.vergote@uzleuven.be, Gilbert, Lucy4 (AUTHOR) lucy.gilbert@mcgill.ca, Martin, Lainie P.5 (AUTHOR) lainie.martin@pennmedicine.upenn.edu, Mantia-Smaldone, Gina M.6 (AUTHOR) gina.mantia-smaldone@fccc.edu, Castro, Cesar M.7 (AUTHOR) cmcastro@mgh.harvard.edu, Provencher, Diane8 (AUTHOR) diane.provencher.med@ssss.gouv.qc.ca, Matulonis, Ursula A.9 (AUTHOR) ursula_matulonis@dfci.harvard.edu, Stec, James10 (AUTHOR) james.stec@immunogen.com, Wang, Yuemei10 (AUTHOR) yuemei.wang@immunogen.com, Method, Michael10 (AUTHOR) michael.method@immunogen.com, O'Malley, David M.1,11 (AUTHOR) david.o'malley@osumc.edu |
| Source: | Gynecologic Oncology. Jun2024, Vol. 185, p186-193. 8p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
